ProtaGene
Integrated Analytical Testing Services for Biopharma & Cell and Gene Therapy – CRO
Goals & Objectives
Private Equity firm Ampersand Capital Partners acquired three CROs based in Europe and the US – Protagen, GeneWerk, and BioAnalytix – and needed to unify the leadership and global operations of the newly formed entity.
Strategic Approach
Our strategy team worked with representatives of all three legacy brands to develop a positioning strategy and messaging for a unified entity: ProtaGene. Based on legacy, ProtaGene was strongly positioned to take advantage of the high-value Omix platform, and we built a state-of-the-art digital integration and go-to-market strategy.
Meeting & Exceeding KPIs
The ProtaGene project was completed in under four months. Since then, ProtaGene has flourished in the post-COVID era, aided by its progressive digital platform, which has supported the unification and growth of the combined business.
